{
    "2018-01-02": [
        [
            {
                "time": "",
                "original_text": "医药生物行业: 注射剂一致性评价来临, 好处高质量龙头公司",
                "features": {
                    "keywords": [
                        "医药生物",
                        "注射剂",
                        "一致性评价",
                        "高质量",
                        "龙头公司"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药行业2018年投资策略：正本清源柳暗花明",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资策略",
                        "2018年",
                        "正本清源"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业周报：首批一致性评价品种出炉把握18年主线投资机会",
                "features": {
                    "keywords": [
                        "医药行业",
                        "一致性评价",
                        "首批品种",
                        "投资机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01",
                "original_text": "【医药】江琦：医药生物行业2018年1月月报：2018是政策落地大年，看好创新药、高品质仿制药、医疗服务三大方向 - 增持 - 0101",
                "features": {
                    "keywords": [
                        "医药生物",
                        "政策落地",
                        "创新药",
                        "高品质仿制药",
                        "医疗服务"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}